{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:33:31Z","timestamp":1794569611399,"version":"4.9.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Novel disease-specific and mechanism-based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic anti-migraine drugs. In this systematic review and meta-analysis, we aimed to identify and rate the evidence for efficacy of flunarizine, a repurposed, first- or second-line treatment for migraine prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic search in MEDLINE, Cochrane CENTRAL, and ClinicalTrials.gov was performed for trials of pharmacological treatment in migraine prophylaxis, following the Preferred Reporting Items for Systematic Reviews (PRISMA). Eligible trials for meta-analysis were randomized, placebo\u2013controlled studies comparing flunarizine with placebo. Outcomes of interest according to the Outcome Set for preventive intervention trials in chronic and episodic migraine (COSMIG) were the proportion of patients reaching a 50% or more reduction in monthly migraine days, the change in monthly migraine days (MMDs), and Adverse Events (AEs) leading to discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five trials were eligible for narrative description and three for data synthesis and analysis. No studies reported the predefined outcomes, but one study assessed the 50% reduction in monthly migraine attacks with flunarizine as compared to placebo showing a benefit from flunarizine with a low or probably low risk of bias. We found that flunarizine may increase the proportion of patients who discontinue due to adverse events compared to placebo (risk difference: 0.02; 95% CI -0.03 to 0.06).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Published flunarizine trials predate the recommended endpoints for evaluating migraine prophylaxis drugs, hence the lack of an adequate assessment for these endpoints. Further, modern-day, large\u2010scale studies would be valuable in re-evaluating the efficacy of flunarizine for the treatment of migraines, offering additional insights into its potential benefits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01657-3","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T23:07:04Z","timestamp":1695078424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention\u2014part 2: flunarizine"],"prefix":"10.1186","volume":"24","author":[{"given":"Christina I.","family":"Deligianni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esme","family":"Ekizoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Uluduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez-del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muizz","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"1657_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF00315132","volume":"40","author":"I Jansen","year":"1991","unstructured":"Jansen I, Tfelt-Hansen P, Edvinsson L (1991) Comparison of the calcium entry blockers nimodipine and flunarizine on human cerebral and temporal arteries: role in cerebrovascular disorders. Eur J Clin Pharmacol 40:7\u201315","journal-title":"Eur J Clin Pharmacol"},{"key":"1657_CR2","doi-asserted-by":"publisher","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","volume":"10","author":"JL Jackson","year":"2015","unstructured":"Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J (2015) A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS ONE 10:e0130733","journal-title":"PLoS ONE"},{"key":"1657_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0014-2999(97)10103-0","volume":"329","author":"K Ayajiki","year":"1997","unstructured":"Ayajiki K, Okamura T, Toda N (1997) Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries. Eur J Pharmacol 329:49\u201353","journal-title":"Eur J Pharmacol"},{"key":"1657_CR4","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/j.1476-5381.1995.tb16624.x","volume":"115","author":"M Shimazawa","year":"1995","unstructured":"Shimazawa M, Hara H, Watano T, Sukamoto T (1995) Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats. Br J Pharmacol 115:1359\u20131368","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1657_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/03331024850050S222","volume":"5","author":"A Wauquier","year":"1985","unstructured":"Wauquier A, Ashton D, Marrannes R (1985) The effects of flunarizine in experimental models related to the pathogenesis of migraine. Cephalalgia 5(2):119\u2013123","journal-title":"Cephalalgia"},{"key":"1657_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0014-2999(91)90526-V","volume":"197","author":"C Ambrosio","year":"1991","unstructured":"Ambrosio C, Stefanini E (1991) Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol 197:221\u2013223","journal-title":"Eur J Pharmacol"},{"key":"1657_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0197-0186(86)90079-3","volume":"9","author":"JE Taylor","year":"1986","unstructured":"Taylor JE, Defeudis FV (1986) Interactions of verapamil, D 600, flunarizine and nifedipine with cerebral histamine-receptors. Neurochem Int 9:379\u2013381","journal-title":"Neurochem Int"},{"issue":"11","key":"1657_CR8","first-page":"770","volume":"43","author":"R Shukla","year":"1995","unstructured":"Shukla R, Garg RK, Nag D, Ahuja RC (1995) Nifedipine in migraine and tension headache: a randomised double blind crossover study. J Assoc Physicians India 43(11):770\u2013772","journal-title":"J Assoc Physicians India"},{"key":"1657_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0306-3623(91)90593-U","volume":"22","author":"J Popova","year":"1991","unstructured":"Popova J, Staneva-Stoytcheva D, Ivanova E, Tosheva T (1991) The long-term treatment with the Ca(2+)-antagonists nifedipine, verapamil, flunarizine and with the calmodulin antagonist trifluoperazine decreases the activity of 5-HT1 receptors in rat cerebral cortex and hippocampus. Gen Pharmacol 22:1147\u20131149","journal-title":"Gen Pharmacol"},{"key":"1657_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/ana.410230512","volume":"23","author":"SJ Peroutka","year":"1988","unstructured":"Peroutka SJ (1988) Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann Neurol 23:500\u2013504","journal-title":"Ann Neurol"},{"key":"1657_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2165\/00003495-198427010-00002","volume":"27","author":"B Holmes","year":"1984","unstructured":"Holmes B, Brogden RN, Heel RC, Speight TC, Avery GS (1984) Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 27:6\u201344","journal-title":"Drugs"},{"key":"1657_CR12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1526-4610.1985.hed2505249.x","volume":"25","author":"WK Amery","year":"1985","unstructured":"Amery WK, Caers LI, Aerts TJ (1985) Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache 25:249\u2013254","journal-title":"Headache"},{"key":"1657_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frse A, Goadsby PJ, Linde M, May A, S\u00e1ndor PS (2009) EFNS guideline on the drug treatment of migraine\u2013revised report of an EFNS task force. Eur J Neurol 16:968\u2013981","journal-title":"Eur J Neurol"},{"key":"1657_CR14","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"1657_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s10194-023-01573-6","volume":"24","author":"C Lampl","year":"2023","unstructured":"Lampl C, Jan Versijpt J, Amin FM, Deligianni CI, Raquel Gil-Gouveia R, Jassal T et al (2023) European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention\u2014part 1: amitriptyline. J Headache Pain 24:39","journal-title":"J Headache Pain"},{"issue":"11","key":"1657_CR16","doi-asserted-by":"publisher","first-page":"e043242","DOI":"10.1136\/bmjopen-2020-043242","volume":"11","author":"K Haywood","year":"2021","unstructured":"Haywood K, Potter R, Froud R, Pearce G, Box B, Muldoon L et al (2021) Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open 11(11):e043242","journal-title":"BMJ Open"},{"key":"1657_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/thoraxjnl-2021-217976","volume":"77","author":"T Pitre","year":"2022","unstructured":"Pitre T, Mah J, Helmeczi W, Khalid MF, Cui S, Zhang M et al (2022) Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax 77:1243\u20131250","journal-title":"Thorax"},{"key":"1657_CR18","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E et al (2020) Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 370:m2980","journal-title":"BMJ"},{"key":"1657_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926","journal-title":"BMJ"},{"key":"1657_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B et al (2020) GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 119:126\u2013135","journal-title":"J Clin Epidemiol"},{"key":"1657_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1526-4610.1981.hed2106235.x","volume":"21","author":"PA Louis","year":"1981","unstructured":"Louis PA (1981) Double-blind Placebo-controlled Prophylactic Study of Flunarizine (Sibelium) in Migraine. Headache 21:235\u2013239","journal-title":"Headache"},{"key":"1657_CR22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0303-8467(84)90273-7","volume":"86","author":"CWGM Frenken","year":"1984","unstructured":"Frenken CWGM, Nuijten STM (1984) Flunarizine, a new preventive approach to migraine. A double-blind comparison with placebo. Clin Neurol Neurosurg 86:17\u201320","journal-title":"Clin Neurol Neurosurg"},{"key":"1657_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1046\/j.1468-2982.1985.0501031.x","volume":"5","author":"G Mendenopoulos","year":"1985","unstructured":"Mendenopoulos G, Manafi Th, Logothetis I, Bostantjopoulou S (1985) Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 5:31\u201337","journal-title":"Cephalalgia"},{"key":"1657_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1046\/j.1468-2982.1986.0601007.x","volume":"6","author":"PS S\u00f8rensen","year":"1986","unstructured":"S\u00f8rensen PS, Hansen K, Olesen J (1986) A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 6:7\u201314","journal-title":"Cephalalgia"},{"key":"1657_CR25","doi-asserted-by":"crossref","unstructured":"Freitag FG, Diamond S, Diamond M. A placebo controlled trial of flunarizine in migraine prophylaxis. Cephalalgia 11(suppl 11): 157\u2013158.","DOI":"10.1177\/0333102491011S1185"},{"key":"1657_CR26","doi-asserted-by":"crossref","unstructured":"International Headache Society Committee on Clinical Trials in Migraine [No authors listed] (1991) Guidelines for controlled trials of drugs in migraine. First edition Cephalalgia 11:1\u201312.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK45458.","DOI":"10.1046\/j.1468-2982.1991.1101001.x"},{"key":"1657_CR27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jama.1962.03050090045008","volume":"179","author":"AdHoc and Committee","year":"1962","unstructured":"AdHoc and Committee (1962) Classification of Headache. JAMA 179:717\u2013718","journal-title":"JAMA"},{"key":"1657_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1468-2982.1981.0103127.x","volume":"1","author":"J Olesen","year":"1981","unstructured":"Olesen J, Krabbe A\u00c6, Tfelt-Hansen P (1981) Methodological aspects of prophylactic drug trials in migraine. Cephalalgia 1:127\u2013141","journal-title":"Cephalalgia"},{"issue":"7","key":"1657_CR29","first-page":"1","volume":"8","author":"Headache Classification Committee of the International Headache Society. [No authors listed]","year":"1988","unstructured":"Headache Classification Committee of the International Headache Society. [No authors listed] (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(7):1\u201396","journal-title":"Cephalalgia"},{"key":"1657_CR30","doi-asserted-by":"publisher","unstructured":"Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, S\u00e1ndor PS. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968\u201381. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02748.x. PMID: 19708964.","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"1657_CR31","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1097\/j.pain.0000000000001456","volume":"160","author":"A Stubberuda","year":"2019","unstructured":"Stubberuda A, Flaaena NM, McCrory DC, Pedersene SA, Linde M (2019) Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 160:762\u2013772","journal-title":"Pain"},{"key":"1657_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M et al (2020) Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. International Headache Society Clinical Trials Committee. Cephalalgia 40:1026\u20131044","journal-title":"Cephalalgia"},{"issue":"5","key":"1657_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1046\/j.1468-2982.1996.1605328.x","volume":"16","author":"J Verspeelt","year":"1996","unstructured":"Verspeelt J, De Locht P, Amery WK (1996) Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia. 16(5):328\u201336","journal-title":"Cephalalgia."},{"issue":"8","key":"1657_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/03331024880080S804","volume":"8","author":"JM Mart\u00ednez-Lage","year":"1988","unstructured":"Mart\u00ednez-Lage JM (1988) Flunarizine (Sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. Cephalalgia. 8(8):15\u201320","journal-title":"Cephalalgia."},{"key":"1657_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1468-2982.2002.t01-1-00309.x","volume":"22","author":"HC Diener","year":"2002","unstructured":"Diener HC, Matias-Guiu J, Hartung E, Pfaffenrath V, Ludin HP, Nappi G, De Beukelaar F (2002) Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 22:209\u2013221","journal-title":"Cephalalgia"},{"issue":"8","key":"1657_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/03331024880080S805","volume":"8","author":"CH L\u00fccking","year":"1988","unstructured":"L\u00fccking CH, Oestreich W, Schmidt R, Soyka D (1988) Flunarizine vs. propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 8(8):21\u201326","journal-title":"Cephalalgia"},{"issue":"10","key":"1657_CR37","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1097\/00005344-199118101-00019","volume":"18","author":"GE Billman","year":"1991","unstructured":"Billman GE (1991) The antiarrhythmic and antifibrillatory effects of calcium antagonists. J Cardiovasc Pharmacol 18(10):S107\u2013S117 (PMID: 1724998)","journal-title":"J Cardiovasc Pharmacol"},{"key":"1657_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fneur.2017.00524.eCollection","volume":"8","author":"F Liu","year":"2017","unstructured":"Liu F, Ma T, Che X, Wang Q (2017) Yu S (2017) The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine. Front Neurol 8:524. https:\/\/doi.org\/10.3389\/fneur.2017.00524.eCollection","journal-title":"Front Neurol"},{"key":"1657_CR39","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","volume":"271","author":"A Lepcha","year":"2014","unstructured":"Lepcha A, Amalanathan S, Augustine AM, Tyagi AK, Balraj A (2014) Flunarizine in the prophylaxis of migrainous vertigo: A randomized controlled trial. Eur Arch Otorhinolaryngol 271:2931\u20132936","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01657-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T18:02:08Z","timestamp":1700416928000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01657-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01657-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}